ReviewAgeing research reviews2017
Molecular pathology endpoints useful for aging studies.
Review in Ageing research reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 57 citations in OpenAlex.
- AUF1 modulates cellular senescence in auditory hair cells by regulating the transcription and alternative splicing of immune response genes.Molecular biology reports · 2026Article
- A cocktail of rapamycin, acarbose, and phenylbutyrate prevents age-related cognitive decline in mice by targeting multiple aging pathways.GeroScience · 2024Article
- Epigenetic and inflammatory markers in older adults with cancer: A Young International Society of Geriatric Oncology narrative review.Journal of geriatric oncology · 2024Review
- Geroscience and Alzheimer's Disease Drug Development.The journal of prevention of Alzheimer's disease · 2023Article
- Biological Age Predictors: The Status Quo and Future Trends.International journal of molecular sciences · 2022Review
- Article
- Effect of Chronic Moderate Caloric Restriction on the Reproductive Function in Aged Male Wistar Rats.Nutrients · 2022Article
- Integrating Environment and Aging Research: Opportunities for Synergy and Acceleration.Frontiers in aging neuroscience · 2022Review
- PathoClock and PhysioClock in mice recapitulate human multimorbidity and heterogeneous aging.Aging pathobiology and therapeutics · 2021Article
- Review
- Strategies to Prevent or Remediate Cancer and Treatment-Related Aging.Journal of the National Cancer Institute · 2021Article
- Ranking Biomarkers of Aging by Citation Profiling and Effort Scoring.Frontiers in genetics · 2021Review
- Proteomic assessment of serum biomarkers of longevity in older men.Aging cell · 2020Article
- Behavioral and Social Research to Accelerate the Geroscience Translation Agenda.Ageing research reviews · 2020Article
- MRI-based biomarkers of accelerated aging and dementia risk in midlife: how close are we?Ageing research reviews · 2020Review
- Reducing Senescent Cell Burden in Aging and Disease.Trends in molecular medicine · 2020Review
- Measuring biological aging in humans: A quest.Aging cell · 2020Review
- Article
- Health and Aging: Unifying Concepts, Scores, Biomarkers and Pathways.Aging and disease · 2019Review
- Metformin prevents murine ovarian aging.Aging · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
The first clinical trial aimed at targeting fundamental processes of aging will soon be launched (TAME: Targeting Aging with Metformin). In its wake is a robust pipeline of therapeutic interventions that have been demonstrated to extend lifespan or healthspan of preclinical models, including rapalogs, antioxidants, anti-inflammatory agents, and senolytics. This ensures that if the TAME trial is successful, numerous additional clinical trials are apt to follow. But a significant impediment to these trials remains the question of what endpoints should be measured? The design of the TAME trial very cleverly skirts around this based on the fact that there are decades of data on metformin in humans, providing unequaled clarity of what endpoints are most likely to yield a positive outcome. But for a new chemical entity, knowing what endpoints to measure remains a formidable challenge. For economy's sake, and to achieve results in a reasonable time frame, surrogate markers of lifespan and healthy aging are desperately needed. This review provides a comprehensive analysis of molecular endpoints that are currently being used as indices of age-related phenomena (e.g., morbidity, frailty, mortality) and proposes an approach for validating and prioritizing these endpoints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.